Tianhong Cui, a lab-on-a-chip and microelectromechanical expert, will join the University of Houston. Photo courtesy University of Minnesota Twin Cities

Thanks to a $4 million grant from the Cancer Prevention and Research Institute of Texas, the University of Houston has recruited a top-tier researcher developing AI-powered lab-on-a-chip technology for early cancer detection.

Tianhong Cui, a professor of mechanical engineering at the University of Minnesota Twin Cities and an adjunct professor of physiology and biomedical engineering at the Mayo Clinic, specializes in microelectromechanical systems and advanced manufacturing at microscale and nanoscale levels. In addition to lab-on-a-chip systems, Cui focuses on biosensors and water sensors.

Lab-on-a-chip devices deliver big results in a tiny package

The CPRIT grant supports Cui’s development of a microscale lab-on-a-chip system for early cancer detection and post-therapy monitoring.

“Lab-on-a-chip technology crams an entire lab’s worth of functions into a tiny device roughly the size of a USB stick,” according to Built In.

Common uses for the technology include medical diagnostics, point-of-care testing, and environmental monitoring.

Lab-on-a-chip work being carried out at UH and elsewhere in Houston promises to revolutionize cancer detection and treatment. For instance, Houston biotech company iBiochips, a spinout from the Houston Methodist Research Institute, makes lab-on-a-chip devices that bolster cancer detection and therapy.

Four local organizations gain $10 million in CPRIT grants

Four other Houston-area organizations received an additional $10 million in grants in CPRIT’s latest round of funding:

  • University of Texas MD Anderson Cancer Center received two $2 million grants to recruit researchers Zheqi Li of Harvard University’s Dana-Farber Cancer Institute and Nikolaos Koundouros of Weill Cornell Medicine.
  • Rice University received one $2 million grant to recruit researcher Maria Akoppyan, formerly of the University of Southern California.
  • UT Medical Branch at Galveston received one $2 million grant to recruit researcher Cristina Santarossa of Johns Hopkins University.
  • Houston-based biopharma company Pulmotect received one $2 million grant to support better outcomes for cancer patients by activating immunity in the lungs as a first line of defense against germs.

The funding was part of $35 million in new CPRIT grants for institutions and companies across Texas approved at the organization's most recent meeting. To date, CPRIT has awarded more than $4.2 billion in grants.

“These awards support research across the cancer continuum from prevention to new classes of therapeutics,” said Dr. Scott Hiebert, chief scientific officer of CPRIT, said in a news release. “The work of these investigators will impact the lives of Texans across the state.”

The Cancer Prevention and Research Institute of Texas has awarded its latest round of grants. Photo via tmc.edu

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.
Houston Methodist has recruited Dr. Daniela Matei, an expert in ovarian and endometrial cancer, to lead the Dr. Mary and Ron Neal Cancer Center. Photo courtesy Houston Methodist.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.
Wei Gao (center), a UH assistant professor of pharmacology, and her team have developed Nano-273, which helps the immune system fight pancreatic and lung cancers. Photo courtesy UH.

Houston team uses CPRIT funding to develop nanodrug for cancer immunotherapy

cancer research

With a relative five-year survival rate of 50 percent, pancreatic cancer is a diagnosis nobody wants. At 60 percent, the prognosis for lung cancer isn’t much rosier. That’s because both cancers contain regulatory B cells (Bregs), which block the body’s natural immunity, making it harder to fight the enemies within.

Newly popular immunotherapies in a category known as STING agonists may stimulate natural cancer defenses. However, they can also increase Bregs while simultaneously causing significant side effects. But Wei Gao, assistant professor of pharmacology at the University of Houston College of Pharmacy, may have a solution to that conundrum.

Gao and her team have developed Nano-273, a dual-function drug, packaged in an albumin-based particle, that boosts the immune system to help it better fight pancreatic and lung cancers. Gao’s lab recently received a $900,000 grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to aid in fueling her research into the nanodrug.

“Nano-273 both activates STING and blocks PI3Kγ—a pathway that drives Breg expansion, while albumin nanoparticles help deliver the drug directly to immune cells, reducing unwanted side effects,” Gao said in a press release. “This approach reduces harmful Bregs while boosting immune cells that attack cancer, leading to stronger and more targeted anti-tumor responses.”

In studies using models of both pancreatic and lung cancers, Nano-273 has shown great promise with low toxicity. Its best results thus far have involved using the drug in combination with immunotherapy or chemotherapy.

With the CPRIT funds, Gao and her team will be able to charge closer to clinical use with a series of important steps. Those include continuing to test Nano-273 alongside other drugs, including immune checkpoint inhibitors. Safety studies will follow, but with future patients in mind, Gao will also work toward improving her drug’s production, making sure that it’s safe and high-quality every time, so that it is eventually ready for trials.

Gao added: “If successful, this project could lead to a new type of immunotherapy that offers lasting tumor control and improved survival for patients with pancreatic and lung cancers, two diseases that urgently need better treatments."

Kristen Doyle, CEO of the Cancer Prevention and Research Institute of Texas (CPRIT). Photo courtesy CPRIT.

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totaling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston ranks No. 2 for share of AI talent in professional services

AI surge

Houston’s professional and business services sector—think law, accounting, consulting, and engineering firms—grabs one of the industry’s biggest shares of AI talent.

A report from commercial real estate services giant CBRE ranks Houston No. 2 among the top 50 U.S. and Canadian tech markets for the concentration of AI talent in professional and business services.

Houston’s share of AI talent in professional and business services stands at 26 percent, the report shows. Washington, D.C., tops the list at 31 percent. At 25 percent, Dallas-Fort Worth claims the No. 3 spot.

CBRE based the AI ranking on data from the LinkedIn networking platform.

The company’s researchers tallied 11,709 AI-related tech jobs in Houston. Nationwide, data scientists lead AI-related job growth in the U.S., according to the report.

“AI software and hardware developers are currently the most sought-after tech talent by employers,” the report says.

Houston faces AI talent gap

DoubleTrack, a provider of AI and data consulting, reported in June that Houston faces an AI talent gap.

“The places where businesses say they will adopt AI over the next six months, well ahead of where they are today, are mostly the same places already short on talent: Miami, Houston, and Denver among the metros, South Dakota and South Carolina among the states,” DoubleTrack said.

This labor shortage comes amid Houston’s ascent as an AI hub. For instance, a factory being built here by AI chipmaker NVIDIA and electronics manufacturer Foxconn will produce AI supercomputers and infrastructure systems.

Houston’s place in the sphere of tech talent

Overall, Houston ranks No. 32 in the CBRE report among the top 50 U.S. and Canadian markets for tech talent. The San Francisco Bay Area claims the top spot, with Austin at No. 5 and DFW at No. 8.

CBRE relied on 13 metrics to rank tech talent markets, including concentration of tech talent, tech talent pipeline, and research-and-development investments.

Here are other Houston details from the report:

  • In 2025, Houston’s tech talent workforce numbered 104,080, up 7.3 percent over the past three years.
  • Houston’s average wage for tech talent within the tech industry was $120,216 in 2025, up 13.3 percent over the past three years.

New pilot program for air taxis, Project Nexus, takes flight in Texas

Project Nexus

By 2029, Texas skies could be buzzing with air taxis, much like they are with drones today.

To kick off the "Project Nexus" pilot program in Texas, U.S. Transportation Secretary Sean Duffy, U.S. Sen. Ted Cruz, and Texas Department of Transportation officials attended an event September 10 at Fort Worth Alliance Airport, which serves as the launchpad for a statewide pilot program that could result in air taxis, self-piloted planes, and vertical take-off-and-landing aircraft permanently buzzing across the skies of Texas.

It was the first demonstration in Texas of next-generation aircraft under the pilot program; Texas is the sixth state to participate in the program.

Air taxi service on the radar
The federal government has teamed up with aviation companies BETA Technologies and Joby Aviation, as well as the Texas Department of Transportation, to develop regional air taxi service in Dallas, Austin, San Antonio, and eventually Houston.

Roger Venables, Fort Worth’s aviation director, said in January that he foresees regular air taxi service becoming a reality in the next five years.

On September 12, a Joby-made electric air taxi took a roundtrip flight between Fort Worth Alliance and Dallas Fort Worth International Airport to test flight operations.

The mission was part of a five-day test involving Fort Worth Alliance and DFW Airport flights, and flights over the Fort Worth Stockyards, Toyota Motor North America’s Plano headquarters, and other sites.

A new facility at Fort Worth Alliance will be Joby’s long-term home for regional flight operations.

Building a 'framework' for electric aircraft
TxDOT said Project Nexus is aimed at creating “a scalable system” to connect urban areas, rural communities, and neighboring states as air mobility technology advances.

In a TxDOT release, Marc Williams, the agency’s executive director, said the pilot program will “build a framework for how electric aircraft could one day connect people, goods, and communities across the state.”

Three-phase project will test flight capabilities

Initial flights in the third-year pilot program won’t carry passengers, according to TxDOT. Instead, the flights will gather data, validate air travel routes, and help improve the safety of air mobility technology.

The first phase of the U.S. Department of Transportation’s Project Nexus will feature piloted aircraft such as helicopters and fixed-wing planes. CultureMap previously reported Plano-based VertiPorts by Atlantic, which develops takeoff and landing sites for airplane-helicopter hybrids, would be part of Project Nexus.

The second phase will involve testing airborne medical and cargo logistics. This includes transporting critical medical supplies or donor organs between rural and urban hospitals in the Austin and San Antonio areas.

In the third and final phase, passengers will fly aboard air taxis across the Texas Triangle. Dallas-Fort Worth, Austin, Houston, and San Antonio anchor the triangle.

“In Texas, we don’t wait for the future to arrive, we build it,” Cruz said in the TxDOT release. “The Lone Star State is pushing the boundaries by testing the next generation of aircraft through Project Nexus.”

“These technologies will connect communities, expand access to jobs and services, and strengthen supply chains,” the senator added. “What starts in Texas will help shape the future of aviation throughout the entire country.”

---

This article originally appeared on CultureMap.com.

Houston-area NASA contractor plans Nasdaq IPO

going public

Webster-based NASA contractor Rothe Development Inc. has filed paperwork with the U.S. Securities and Exchange Commission to go public.

Rothe, a minority- and woman-owned business, hasn’t yet identified how many shares it will sell and how much money its IPO might raise. Rothe plans to offer Class B common stock on the Nasdaq exchange.

CEO Karen Wheeler-Hall owns all of the Class A shares and would retain majority control after the IPO, according to the SEC filing. The company plans to use $2.4 million of the IPO proceeds so Wheeler-Hall can pay off a loan from the seller for her 2021 acquisition of Rothe.

From last December to this May, the company raised about $2.1 million in a pre-IPO private placement at $1 per share, the SEC filing shows.

Rothe runs NASA training lab in Houston

Founded in 1967, Rothe supplies engineering, technology, operations and technical services to NASA, the U.S. Department of Defense, other federal agencies, commercial space operators, and regulated industries.

Rothe is likely best known for operating NASA’s Neutral Buoyancy Laboratory in Houston. The lab trains astronauts for spacewalks and simulates space missions. It supports NASA’s International Space Station and Artemis programs.

Company sees room for growth

In the SEC filing, Rothe said it operates in several expanding markets driven by rising investments, including space exploration, national security, cybersecurity and digital infrastructure.

“We believe these market trends create significant opportunities for continued growth across both government and commercial sectors,” the company said.

Rothe generated nearly $126.4 million in revenue last year, up from $117.3 million the previous year. However, the company swung to a $700,000 operating loss in 2025 versus $1.8 million in operating income in 2024.

At the end of 2025, Rothe’s workforce comprised 385 employees and 25 subcontractors. The company also works in the cybersecurity, computer engineering, software development, multimedia and communication, and commercial calibration sectors, according to its website.